ZTSZoetis

Kristin Peck , Chief Executive Officer , adopted a pre-arranged trading plan on September 12, 2025 , that is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Ms. Peck's plan provides for: (i) the sale of up to 20,000 shares of Zoetis common stock between January 2, 2026 and February 18, 2026, upon the exercise of certain vested stock options that have an expiration date of February 18, 2026, (ii) the sale of up to 22,500 shares of Zoetis common stock between March 17, 2026 and December 31, 2026, and (iii) the gifting of up to $300,000 worth of Zoetis common stock to a charitable fund between January 2, 2026 and December 31, 2026.

Roxanne Lagano, Executive Vice President, General Counsel and Corporate Secretary, adopted a pre-arranged trading plan on September 13, 2024, that is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Ms. Lagano’s plan provides for the sale of (i) between December 16, 2024 and December 16, 2025, up to 4,339 shares of Zoetis common stock and (ii) between February 11, 2025 and December 16, 2025, 100% of the net shares (net of tax withholding) resulting from the vesting of 4,858 gross shares of Zoetis common stock relating to equity awards, subject to certain conditions.

Kristin Peck, Chief Executive Officer, adopted a pre-arranged trading plan on September 12, 2024, that is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Ms. Peck's plan provides for (i) the sale of up to 52,000 shares of Zoetis common stock between December 13, 2024 and December 31, 2025 and (ii) the gifting of up to $300,000 worth of Zoetis common stock to a charitable fund between December 13, 2024 and December 31, 2025.

On May 8, 2024, Kristin Peck, Chief Executive Officer, terminated a pre-arranged trading plan that was intended to satisfy the affirmative defense of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Ms. Peck’s terminated plan provided for (i) the sale of up to 52,000 shares of Zoetis common stock between May 21, 2024 and April 30, 2025 and (ii) the gifting of up to $300,000 worth of Zoetis common stock to a charitable fund between May 21, 2024 and April 30, 2025.

Heidi Chen, Executive Vice President, General Counsel and Corporate Secretary; Business Lead of Human Health Diagnostics, adopted a pre-arranged trading plan on December 15, 2023, that is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Ms. Chen's plan provides for the sale of up to 8,310 shares of Zoetis common stock between March 15, 2024 and March 13, 2026.